7. A composition for use according to any of the preceding claims, wherein the subject is suffering from a nerve injury of genetic origin.

8. A composition for use according to claim 7, wherein the subject is suffering from a Charcot-Marie-Tooth disease.

9. A composition for use according to any of the preceding claims, comprising less than 4 mg of torasemide.

10. A composition for use according to any of the preceding claims, comprising less than 150 mg of baclofen, preferably less than 50mg.

11. A composition of any one of claims 1-6, for use in treating neurapraxia, axonometsis or neurotmesis.

12. ~~A method of promoting nerve or neuron regeneration in a subject in need thereof, comprising administering to said subject torasemide and baclofen, or salts, prodrugs, derivatives, or sustained release formulations thereof.~~ Use of torasemide and baclofen, or salts, prodrugs, derivatives, or sustained release formulations thereof, for promoting nerve or neuron regeneration in a subject in need thereof.

13. The ~~method~~ use of claim 12, ~~which~~ further ~~comprises administering~~ comprising using a pharmaceutically acceptable carrier or excipient.

~~14. The method of claims 12, comprising administering simultaneously, separately or sequentially torasemide and baclofen to the subject.~~

~~15.~~14. The ~~method~~ use of claim 12, wherein the subject is suffering from a nerve injury of genetic origin.

~~16.~~15. The ~~method~~ use of claim 12, wherein the subject is suffering from a Charcot-Marie-Tooth disease.

~~17.~~16. The ~~method~~ use of claim 12, wherein the subject is suffering from neurapraxia, axonometsis or neurotmesis.

~~18.~~17. The ~~method~~ use of claim 12, ~~comprising administering less than~~ ~~comprising~~where the torasemide is less than 4 mg ~~of torasemide~~.

~~19.~~18. The ~~method~~ use of claim 12, ~~comprising administering less than~~ ~~comprising~~where the baclofen is less than 150 mg ~~of baclofen~~, preferably less than 50mg.